Xavier Quantin
Overview
Explore the profile of Xavier Quantin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
72
Citations
4182
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Justeau G, Chouaid C, Debieuvre D, Audigier-Valette C, Quantin X, Lena H, et al.
Front Oncol
. 2025 Mar;
15:1526931.
PMID: 40052124
Introduction: This study describes treatment and retreatment patterns and outcomes in patients in France following nivolumab as a second-line or later (2L+) treatment in locally advanced or metastatic non-small cell...
2.
Thomas Q, Girard N, Bosquet L, Cavaillon S, Filleron T, Eltaief S, et al.
Cancers (Basel)
. 2024 Nov;
16(21).
PMID: 39518004
Osimertinib, a third-generation tyrosine kinase inhibitor (TKI), demonstrated superior efficacy over first-generation TKIs in the FLAURA trial, resulting in its approval as first-line therapy for metastatic non-small-cell lung cancer (NSCLC)....
3.
Hountondji L, Faure S, Palassin P, Viel P, Dupuy M, Larrey D, et al.
Aliment Pharmacol Ther
. 2024 Sep;
60(11-12):1561-1572.
PMID: 39315730
Background And Aims: While immune checkpoint inhibitors (ICIs) are revolutionising cancer therapy, checkpoint inhibitor-induced liver injury is a significant immune-related side effect of this immunotherapy. This study focuses on the...
4.
Hermabessiere S, Palassin P, Quantin X, Maria A, Coustal C
Bull Cancer
. 2024 Sep;
111(10):989-991.
PMID: 39261249
No abstract available.
5.
Cabart M, Mourey L, Pasquier D, Schneider S, Lena H, Girard N, et al.
J Geriatr Oncol
. 2024 Jul;
15(7):101819.
PMID: 39068144
Introduction: In France, 40% of patients diagnosed with lung cancer are ≥70 years old, but these are under-represented in clinical trials. Using data from the French Epidemiological Strategy and Medical...
6.
Neal J, Pavlakis N, Kim S, Goto Y, Lim S, Mountzios G, et al.
J Clin Oncol
. 2024 Mar;
42(20):2393-2403.
PMID: 38552197
Purpose: Although checkpoint inhibitors have improved first-line treatment for non-small cell lung cancer (NSCLC), a therapeutic need remains for patients whose disease does not respond or who experience disease progression...
7.
Thomas Q, Chaabouni M, Al Herk A, Lefevbre C, Cavaillon S, Sinoquet L, et al.
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473356
Introduction: Immune checkpoint blockers have revolutionized the first-line treatment of advanced non-small-cell lung cancer (NSCLC). Pembrolizumab, an anti-PD-1 monoclonal antibody, is a standard therapy either alone or in combination with...
8.
Sauvageot S, Mollevi C, Thomas Q, Charissoux M, Darlix A, Rigau V, et al.
J Neurosurg
. 2024 Jan;
141(1):89-99.
PMID: 38241682
Objective: Systemic therapeutic advancements have improved the prognosis of cancer patients, leading to surgery more frequently being carried out for patients with multiple brain metastases (BM). The underlying evidence for...
9.
Yang J, Han B, de la Mora Jimenez E, Lee J, Koralewski P, Karadurmus N, et al.
J Thorac Oncol
. 2023 Dec;
19(6):941-953.
PMID: 38159809
Introduction: Lenvatinib plus pembrolizumab was found to have antitumor activity and acceptable safety in previously treated metastatic NSCLC. We evaluated first-line lenvatinib plus pembrolizumab versus placebo plus pembrolizumab in metastatic...
10.
Flaudias V, Gonthier C, Picot M, Llorca P, Schmitt A, Perriot J, et al.
Addict Behav
. 2023 Dec;
151:107940.
PMID: 38134598
Objectives: Understanding the factors that lead to relapse is a major challenge for the clinical support of smoking cessation. Neurocognitive abilities such as attention, executive functioning and working memory, are...